Contact
searchSearch
HMP Global
Login

Oncology

Featured

Filippo Pietrantonio, MD
Videos
ctDNA Clearance Predicts Outcomes in KRAS G12C-Mutated Metastatic Colorectal Cancer
06/09/2026
Filippo Pietrantonio
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD,...
06/09/2026
Oncology
Quiz
Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
News
New Conceptual Model Captures Patient Experience in Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.
Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.
Results from a qualitative study...
06/08/2026
Oncology
News
Real-World Analysis Identifies Challenges With Phlebotomy-Based Management of Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.
Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.
Results from a retrospective...
06/08/2026
Oncology
News
Higher Starting Dose of Ropeginterferon Accelerates Responses in Patients With Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.
Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.
Results from a systematic review...
06/08/2026
Oncology
News
Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3...
06/08/2026
Oncology
News
Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective...
06/08/2026
Oncology
Guilherme Rabinowits, MD
Videos
FID-007 Plus Cetuximab Demonstrates Encouraging Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/05/2026
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD,...
06/05/2026
Oncology
Anastasios Maniakas, MD, PhD
Videos
ASP-1929 Photoimmunotherapy Demonstrates Clinical Benefit in Recurrent Head and Neck Squamous Cell Carcinoma
06/05/2026
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD,...
06/05/2026
Oncology
Barbara Burtness, MD, FASCO
Videos
Amivantamab Demonstrates Durable Responses in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
06/05/2026
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO,...
06/05/2026
Oncology

Videos

Filippo Pietrantonio, MD
Videos
ctDNA Clearance Predicts Outcomes in KRAS G12C-Mutated Metastatic Colorectal Cancer
06/09/2026
Filippo Pietrantonio
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD,...
06/09/2026
Oncology
Guilherme Rabinowits, MD
Videos
FID-007 Plus Cetuximab Demonstrates Encouraging Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/05/2026
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD,...
06/05/2026
Oncology
Anastasios Maniakas, MD, PhD
Videos
ASP-1929 Photoimmunotherapy Demonstrates Clinical Benefit in Recurrent Head and Neck Squamous Cell Carcinoma
06/05/2026
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD,...
06/05/2026
Oncology
Barbara Burtness, MD, FASCO
Videos
Amivantamab Demonstrates Durable Responses in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
06/05/2026
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO,...
06/05/2026
Oncology
Scott Kopetz, MD, PhD
Videos
Encorafenib and Cetuximab Plus FOLFIRI Improves Outcomes in BRAF V600E-Mutant Metastatic Colorectal Cancer
06/04/2026
Scott Kopetz, MD, PhD
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO, discusses phase 3 BREAKWATER Cohort 3 results showing that first-line encorafenib plus cetuximab and FOLFIRI improved response rates, progression-free survival, and overall survival vs standard therapy in BRAF...
Scott Kopetz, MD, PhD, FASCO,...
06/04/2026
Oncology
Daniel D'Angelo, MD
Videos
Novel Immunotherapy Combination Improves MRD-Negative Rates in B-Cell Acute Lymphoblastic Leukemia
06/03/2026
Daniel DeAngelo, MD, PhD
Daniel DeAngelo, MD, discusses data showing that the addition of inotuzumab ozogamicin to modified hyper-CVAD plus blinatumomab produced high remission and MRD-negative response rates with low relapse rates in patients with B-cell acute...
Daniel DeAngelo, MD, discusses data showing that the addition of inotuzumab ozogamicin to modified hyper-CVAD plus blinatumomab produced high remission and MRD-negative response rates with low relapse rates in patients with B-cell acute...
Daniel DeAngelo, MD, discusses...
06/03/2026
Oncology
John Mascarenhas, MD
Videos
Selinexor Plus Ruxolitinib Demonstrates Clinical Benefit in JAK Inhibitor–Naïve Myelofibrosis
06/03/2026
John Mascarenhas, MD
John Mascarenhas, MD, discusses results from the phase 3 SENTRY trial showing that the addition of selinexor to ruxolitinib improved spleen responses, enhanced molecular response rates, and demonstrated an early overall survival signal in JAK...
John Mascarenhas, MD, discusses results from the phase 3 SENTRY trial showing that the addition of selinexor to ruxolitinib improved spleen responses, enhanced molecular response rates, and demonstrated an early overall survival signal in JAK...
John Mascarenhas, MD, discusses...
06/03/2026
Oncology
Ronald Chen, MD, MPH
Videos
Pembrolizumab Improves DFS Without Compromising HRQOL in High-Risk Muscle-Invasive Urothelial Carcinoma
06/01/2026
Ronald Chen, MD, MPH, FASCO
Ronald Chen, MD, reviews results from the AMBASSADOR trial showing that adjuvant pembrolizumab improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma without negatively affecting health-related quality...
Ronald Chen, MD, reviews results from the AMBASSADOR trial showing that adjuvant pembrolizumab improved disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma without negatively affecting health-related quality...
Ronald Chen, MD, reviews results...
06/01/2026
Oncology
Glenn Hanna, MD
Videos
Emi-Le Demonstrates Promising Activity in Aggressive Adenoid Cystic Carcinoma
06/01/2026
Glenn Hanna, MD
Glenn Hanna, MD, discusses promising phase 1 results for emiltatug ledadotin (Emi-Le; XMT-1660), a novel B7-H4-directed antibody-drug conjugate that demonstrated encouraging efficacy and a favorable safety profile in patients with aggressive...
Glenn Hanna, MD, discusses promising phase 1 results for emiltatug ledadotin (Emi-Le; XMT-1660), a novel B7-H4-directed antibody-drug conjugate that demonstrated encouraging efficacy and a favorable safety profile in patients with aggressive...
Glenn Hanna, MD, discusses...
06/01/2026
Oncology
Brian Wolpin, MD
Videos
Daraxonrasib Improves Survival Outcomes in Previously Treated Metastatic Pancreatic Cancer
05/31/2026
Brian Wolpin, MD, MPH, presents results from the phase 3 RASolute 302 trial showing daraxonrasib significantly improved overall survival, progression-free survival, and response rates vs standard chemotherapy in previously treated metastatic...
Brian Wolpin, MD, MPH, presents results from the phase 3 RASolute 302 trial showing daraxonrasib significantly improved overall survival, progression-free survival, and response rates vs standard chemotherapy in previously treated metastatic...
Brian Wolpin, MD, MPH, presents...
05/31/2026
Oncology

Insights From the ASCO Annual Meeting

Filippo Pietrantonio, MD
Videos
ctDNA Clearance Predicts Outcomes in KRAS G12C-Mutated Metastatic Colorectal Cancer
06/09/2026
Filippo Pietrantonio
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD, discusses post hoc analysis results from the CodeBreaK 300 trial which showed that early ctDNA clearance strongly correlates with tumor response and improved survival outcomes in patients with KRAS G12C-mutated...
Filippo Pietrantonio, MD,...
06/09/2026
Oncology
News
New Conceptual Model Captures Patient Experience in Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.
Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.
Results from a qualitative study...
06/08/2026
Oncology
News
Real-World Analysis Identifies Challenges With Phlebotomy-Based Management of Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.
Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.
Results from a retrospective...
06/08/2026
Oncology
News
Higher Starting Dose of Ropeginterferon Accelerates Responses in Patients With Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.
Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.
Results from a systematic review...
06/08/2026
Oncology
News
Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3...
06/08/2026
Oncology
News
Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective...
06/08/2026
Oncology
Guilherme Rabinowits, MD
Videos
FID-007 Plus Cetuximab Demonstrates Encouraging Activity in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/05/2026
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD, discusses results from a phase 2 trial which demonstrated that FID-007 plus cetuximab showed promising activity and manageable safety in patients with recurrent or metastatic head and neck squamous cell carcinoma who...
Guilherme Rabinowits, MD,...
06/05/2026
Oncology
Anastasios Maniakas, MD, PhD
Videos
ASP-1929 Photoimmunotherapy Demonstrates Clinical Benefit in Recurrent Head and Neck Squamous Cell Carcinoma
06/05/2026
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD, discusses results from a phase 3 study which found that ASP-1929 photoimmunotherapy improved response and quality-of-life outcomes in recurrent head and neck squamous cell carcinoma.
Anastasios Maniakas, MD, PhD,...
06/05/2026
Oncology
Barbara Burtness, MD, FASCO
Videos
Amivantamab Demonstrates Durable Responses in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
06/05/2026
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO, discusses phase 2 OrigAMI-4 results showing that subcutaneous amivantamab achieved a 47% response rate in HPV-unrelated recurrent/metastatic head and neck squamous cell carcinoma after progression on...
Barbara Burtness, MD, FASCO,...
06/05/2026
Oncology
News
Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/05/2026
Emily Estrada
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study...
06/05/2026
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

News
New Conceptual Model Captures Patient Experience in Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.
Results from a qualitative study demonstrated that patients with polycythemia vera experience substantial symptom burden and quality-of-life impairment.
Results from a qualitative study...
06/08/2026
Oncology
News
Real-World Analysis Identifies Challenges With Phlebotomy-Based Management of Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.
Results from a retrospective real-world analysis demonstrated that phlebotomy remains widely used in the management of polycythemia vera, despite substantial treatment burden and challenges achieving durable hematocrit control.
Results from a retrospective...
06/08/2026
Oncology
News
Higher Starting Dose of Ropeginterferon Accelerates Responses in Patients With Polycythemia Vera
06/08/2026
Stephanie Holland
Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.
Results from a systematic review and meta-analysis demonstrated that high initial dose and accelerated titration of ropeginterferon was associated with faster hematologic and molecular responses in patients with polycythemia vera.
Results from a systematic review...
06/08/2026
Oncology
News
Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3...
06/08/2026
Oncology
News
Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective...
06/08/2026
Oncology
News
Eganelisib Demonstrates Early Activity in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/05/2026
Emily Estrada
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study demonstrated that eganelisib showed promising preliminary activity in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Results from a phase 1 study...
06/05/2026
Oncology
News
Fedratinib Demonstrates Potential Clinical Promise in Patients With Proliferative MDS/MPNs and Chronic Neutrophilic Leukemia
06/05/2026
Emily Estrada
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study demonstrated that fedratinib showed promising clinical activity among patients with myelodysplastic and myeloproliferative neoplasms and chronic neutrophilic leukemia.
Results from a phase 2 study...
06/05/2026
Oncology
News
Fluoxetine Plus Chemoradiotherapy Shows Potential Activity in Newly Diagnosed High-Grade Glioma
06/05/2026
Emily Estrada
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study suggest that the addition of fluoxetine to standard chemoradiotherapy was feasible and had manageable toxicity among newly diagnosed patients with grade 4 glioma.
Results from a phase 2 study...
06/05/2026
Oncology
News
ACT001 Plus Radiotherapy Shows Strong Clinical Promise in Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma
06/05/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial demonstrated that ACT001 combined with radiotherapy showed encouraging clinical promise in newly diagnosed pediatric patients with diffuse intrinsic pontine glioma.
Results from a phase 2 trial...
06/05/2026
Oncology
News
Enfortumab Vedotin Plus Pembrolizumab Maintains Long-Term Survival Benefit in Advanced Urothelial Carcinoma
06/01/2026
Emily Estrada
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the EV-302/KEYNOTE-A39 trial demonstrated that enfortumab vedotin plus pembrolizumab maintained a durable survival benefit in previously untreated patients with locally advanced or metastatic urothelial carcinoma.
Results from the...
06/01/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use